Authors
Loading...
Systematic review and meta-analysis highlights tocilizumab's potential to reduce cytokine release syndrome in patients treated with CAR-T and bispecific antibodies.
Shahzad et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: